Black Diamond Therapeutics Q1 Revenue Drops to $0, Posts $9.04M Net Loss
summarizeSummary
Black Diamond Therapeutics reported Q1 2026 financial results with $0 in license revenue and a net loss of $9.04 million, or ($0.16) diluted EPS. This represents a significant year-over-year decline from Q1 2025, which benefited from $70 million in license revenue and a $56.54 million net income, largely due to the BDTX-4933 outlicensing deal. The 2025 annual report highlighted a major turnaround driven by this deal, making the current quarter's $0 revenue a stark contrast. While the company highlighted clinical progress for silevertinib and reduced operating expenses, the absence of significant revenue generation in the quarter underscores its reliance on future milestone payments or new partnerships. Despite the current loss, the company maintains a cash runway into the second half of 2028. Traders will monitor future clinical trial readouts and potential new licensing agreements for revenue catalysts.
At the time of this announcement, BDTX was trading at $2.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $161.6M. The 52-week trading range was $1.46 to $4.94. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.